Dr. Griffin Rodgers, Director of the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases, is an accomplished clinician, researcher, and mentor, and is a role model.

His research interests include genetic diseases: sickle cell anemia, thalassemia, red cell enzymopathies; clinical evaluation of disease severity; treatment, including pharmacological alteration of gene expression and stem cell transplantation; molecular genetics of human hemoglobins; gene expression and differentiation in erythroid cells in normal and perturbed hematopoietic states; pharmacological alteration of gene expression; molecular genetics of myleodysplastic and myleoproliferative syndromes; hematopoiesis; role of inducible and stochastic factors; hematopoietic stem cell plasticity; identification of early markers of lineage-specific differentiation; the development of novel gene therapy strategies and their targeted application in cord blood hematopoietic stem cells.

As a research investigator, Dr. Rodgers is widely recognized for his contributions to the development of hydroxyurea, the first effective—and now FDA approved—therapy for sickle cell anemia.

Representative Publications:

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease

HbA2 : biology, clinical relevance and a possible target for ameliorating sickle cell disease

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia

Hemolytic anemia-associated pulmonary hypertension in sickle cell disease

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder